io103
Vaccineexperimental
Clinical trial activity
1 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Dec 31, 2021 (NCT05155254)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Indoleamine 2,3-dioxygenaseImmunity, active
IDO1 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05155254 | Phase 3 | Dec 31, 2021 | Almac Clinical Services LLC, IO Biotech, Klifo A/S, Merck, Syneos Health, University of Copenhagen |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Almac Clinical Services LLC | For profit | 1 | 0 | 1 | 2021 |
| IO Biotech | For profit | 1 | 1 | 1 | 2021 |
| Klifo A/S | For profit | 1 | 0 | 1 | 2021 |
| Merck | For profit | 1 | 0 | 1 | 2021 |
| Syneos Health | For profit | 1 | 0 | 1 | 2021 |
| University of Copenhagen | Academic/Hospital | 1 | 0 | 1 | 2021 |
6 organizations
Page 1 / 1